


**Westminster Health Forum policy conference:
Pharmaceutical pricing and access to medicines**

Timing: Morning, Thursday, 25th April 2019

Venue: Congress Centre, 28 Great Russell Street, London WC1B 3LS



**WESTMINSTER
HEALTH FORUM**

Agenda subject to change

- 8.30 - 9.00 Registration and coffee
- 9.00 - 9.05 **Chair's opening remarks**
Baroness Jolly, Liberal Democrat Lords Spokesperson for Health
- 9.05 - 9.35 **The Voluntary Scheme for Branded Medicines Pricing and Access - key aims**
Robert Kettell, Deputy Director, Medicines Pricing, Department of Health and Social Care
Questions and comments from the floor
- 9.35 - 10.05 **'Industry perspective on the Voluntary Scheme for Branded Medicines Pricing and Access'**
Paul Catchpole, Director of Value and Access, ABPI
David Watson, Director of Pricing and PPRS, ABPI
Questions and comments from the floor
- 10.05 - 10.55 **Bringing new products to the market - price control, the impact of the Accelerated Access Collaborative and preparing for Brexit**
Paul Ranson, Consultant, Morgan Lewis
Keith Jordan, Communications, Policy and Access Director, Roche
Robert Whitemore, Director, Roboleo & Co
Bhulesh Vadher, Clinical Director of Pharmacy, Oxford University Hospitals NHS Foundation Trust
Questions and comments from the floor
- 10.55 - 11.00 **Chair's closing remarks**
Baroness Jolly, Liberal Democrat Lords Spokesperson for Health
- 11.00 - 11.25 Coffee
- 11.25 - 11.30 **Chair's opening remarks**
Anne Marie Morris MP, Chair, All-Party Parliamentary Group on Access to Medicines and Medical Devices
- 11.30 - 11.40 **'How research and innovation can shape access to cancer drugs'**
Professor Paul Workman, Chief Executive and President, The Institute of Cancer Research
- 11.40 - 11.50 **Meeting patient choice - and implications for cost**
Nick Medhurst, Head of Policy and Public Affairs, Cystic Fibrosis Trust
- 11.50 - 12.00 **Value-based pricing, reimbursement and supply chains - challenges for industry**
Dr Stuart Dollow, Founder, Vermilion Life Sciences
- 12.00 - 12.10 **Emerging forms of competition - evaluating the uptake of biosimilars**
Professor Mike Hannay, Managing Director, East Midlands Academic Health Science Network
- 12.10 - 12.30 Questions and comments from the floor
- 12.30 - 12.55 **Next steps in assessing cost effectiveness - priorities for NICE**
Meindert Boysen, Director, Centre for Health Technology Evaluation, NICE
Questions and comments from the floor
- 12.55 - 13.00 **Chair's and Westminster Health Forum closing remarks**
Anne Marie Morris MP, Chair, All-Party Parliamentary Group on Access to Medicines and Medical Devices
Michael Ryan, Deputy Editor, Westminster Health Forum